|25.13 0.39 (1.58%)||12-01 16:00|
|Targets||6-month :||29.8||1-year :||34.8|
|Resists||First :||25.51||Second :||29.8|
|Supports||First :||21.98||Second :||19.8|
|MAs||MA(5) :||24.33||MA(20) :||23.91|
|MA(100) :||23.28||MA(250) :||20.87|
|MACD||MACD :||0.6||Signal :||0.5|
|%K %D||K(14,3) :||73.4||D(3) :||67.8|
|52-week||High :||27.7||Low :||12.43|
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ MRUS ] has closed below upper band by 2.8%. Bollinger Bands are 36% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
|If tomorrow:||Open lower||Open higher|
|High:||25.48 - 25.58||25.58 - 25.69|
|Low:||24.03 - 24.13||24.13 - 24.25|
|Close:||24.93 - 25.1||25.1 - 25.3|
Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; and collaboration with Incyte Corporation for the development of MCLA-145. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.
|Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
|Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
|Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
|Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
|Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
|Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
|Shares Out||58 (M)|
|Shares Float||42 (M)|
|Held by Insiders||8.3 (%)|
|Held by Institutions||83.8 (%)|
|Shares Short||6,540 (K)|
|Shares Short P.Month||4,650 (K)|
|EPS Est Next Qtrly||0|
|EPS Est This Year||0|
|EPS Est Next Year||0|
|Book Value (p.s.)||6.8|
|Profit Margin||0 %|
|Operating Margin||-347.8 %|
|Return on Assets (ttm)||-22.5 %|
|Return on Equity (ttm)||-51.1 %|
|Qtrly Rev. Growth||67.5 %|
|Gross Profit (p.s.)||-1.87|
|Sales Per Share||0.79|
|Qtrly Earnings Growth||0 %|
|Operating Cash Flow||-136 (M)|
|Levered Free Cash Flow||-79 (M)|
|Price to Book value||3.69|
|Price to Sales||31.76|
|Price to Cash Flow||-10.64|
|Dividend Pay Date||Invalid DateTime.|
|Ex-Dividend Date||Invalid DateTime.|